medigraphic.com
ISSN 0016-3813 (Print)

2003, Number 3

<< Back Next >>

Gac Med Mex 2003; 139 (3)

The Future of Blood Transfusión. Transmissible Diseases Symposium

I. Update in Transfusión Safety.
II. Eneerging Infections in Blood Transfusion.
III. Eneerging Infections in Blood Transfusion.
IV. Leukoreduction of Blood Products.

Bravo LA, Valencia P, Pacheco RA, Romero-López D

Language: Spanish
References: 47
Page: 81-92
PDF size: 99.18 Kb.


Text Extraction

No abstratc


REFERENCES

  1. Safety of blood derived products.10Th International Conference of Drug Regulatory Authorities (ICDRA). World Health Organization and of the Government of the People’s Republic of China. Hong Kong, China: 24-27 June 2002. 25–32. http://whqlibdoc.who.int/hq/2003

  2. Ballow M. Intravenous immunoglobulins: clinical experience and viral safety. J Am Pharma Assoc 2002;42:450-459.

  3. Bravo LA. Métodos de inactivación de patógenos en productos celulares sanguíneos. Gac Med Mex 2003;139(Suppl 2):24-27.

  4. Mannucci P. Hemophilia and related bleeding disorders: a story of dismay and success. Ham Wasserman Lecture. American Society of Hematology. Education Program Book. Hematology 2002. p. 1-9.

  5. Ganem F. Inactivación viral de la sangre y sus derivados: actualidades. Univ Diag 2002;2(2):11-5.

  6. Farrugia A. Guía para la evaluación de concentrados de factores de coagulación para el tratamiento de la hemofilia. Federación Mundial de Hemofilia; 2003.

  7. Feigin RD, CherryJD. Textbook of pediatric infectious diseases. Philadelphia, USA: WB Saunders Company; 1998.

  8. Hart A, Beeching NJ. Curr Opin Infect Dis 2002;15:497-500.

  9. Lawrence TG, Brecher ME, Kanter MH, Aubuchon JP. Transfusion Medicine. Blood Transfus N Engl J Med 1999;340:438-447.

  10. Choudhury N, Phadke S. Transfusion transmitted diseases. Indian J Pediatr 2001;68:951-958.

  11. Gresens CJ, Holland PV. The disappearance of transfusion-transmitted hepatitis C virus infections in the United States. Clin Liver Dis 2001;5:1105-1113.

  12. Weusten JJ, Van Drimmelen HA, Lelie PN. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion 2002;42:537-548.

  13. Morales Aguirre JJ, Cashat CM, Huguette EM, Solís AM, Villalobos AP, Valencia MP. Síndrome agudo respiratorio grave. Implicaciones en pediatría. Bol Med Hosp Infant Mex 2003;60:535-542.

  14. Challine D, Roudot-Thoraval F, Sarah T y cols. Seroprevalence of human herpes virus 8 antibody in population at high or low risk of transfusion, graft, or sexual transmission viruses. Transfusion 2001 Sep;41(9):1120-1125.

  15. Connor DH, Chandler FW, Dchwartz DA, ManzHJ, Lack EE. Pathology of infectious diseases. Stanford, CA, USA: Appleton & Lange; 1997.

  16. Haykawa F, Imada K, Towatari M, Saito H. Life-threatening human parvovirus B19 infection transmitted intravenous immune globulin. Br J Haematol 2002;118:1187-1189.

  17. CDC: www. cdc.gov/incidod/dvbid/westnile.

  18. Ironside JW, Head MW. Variant Creutzfeldt-Jakob disease and its transmission by blood. J Thromb Haemost 200;7:1479-1486.

  19. Leiby DA, Herron RM, Read EJ, Lenes BA, Stumpf RJ. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 2002;42:549-555.

  20. Klein HG, Dodd RY, Ness PM, et al. Current status of microbial contamination of blood components: summary of a conference. Transfusion 1997;37:95-101.

  21. Sohn AH, Shay DK, Banerjee SN, Jarvis WR. Clinical syndromes of hospital associated infection. In: Long SS, Pickering LK, Prober CG, editors. Principles and practice of pediatric infectious diseases. 2nd ed. New York: Churchill Livingstone; Inc, 2003. p. 582-605.

  22. Goldman M, Blajchman MA. Blood product-associated bacterial sepsis. Transfus Med Rev 1991;5:73-83.

  23. Straus SE. Human herpesvirus type 8 (Kaposi’s sarcoma-associated herpesvirus). En: Mandell GL, Bennet JE, Dolin R. Principles and practice of infectious diseases. 5th ed. New York: Churchill Livingstone Inc, 2000:2: 618-1620.

  24. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994;266:1865-1869.

  25. Moore PS, Gao SJ, Dominguez G, et al. Primary characterization of a herpesvirus agent associated with Kaposi’s sarcoma. J Virol 1996;70:549-558.

  26. Blasig C. Ziets C, Haar B, et al. Monocytes in Kaposi’s sarcoma lesions are productively infected by human herpesvirus 8. J Virol 1997;71:7963-7968.

  27. Davis DA, Humphrey RW, Newcomb FM, et al. Detection of serum antibodies to a Kaposi’s sarcoma-associated herpesvirus-specific peptide. J Infect Dis 1997;175:1071-1079.

  28. Roback JD. Infectious complications of transfusion. CMV and other herpesviruses. In: Hillyer CD, Hillyer KL, Strobl FJ, Jefferies LC, Silberstein LE. Handbook of transfusion medicine. San Diego, CA, USA: Academic Press; 2001. p. 285-292.

  29. Blackbourn DJ, Ambroziak J, Lennette E, et al. Infectious human herpesvirus 8 in a healthy North American blood donor. Lancet 1997;349:609-611.

  30. Regamey N, Tamm M, Wernli M, et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 1998;339:1358-1363.

  31. Tyler KL. Prions diseases of the central nervous system (transmissible neurodegenerative diseases). In: Mandell GL, Bennet JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. New York: Churchill Livingstone Inc, 2000;2:1971-1985.

  32. Prusiner SB. Prions diseases and the BSE crisis. Science 1997;278:245-251.

  33. Britton TC, Al-Sarraj S, Shaw C, et al. Sporadic Creutzfeld-Jakob disease in one 16-year-old in the UK. Lancet 1995;346:1181.

  34. Zeidler M, Stewart GE, Barraclough CR, et al. New variant Creutzfeld-Jakob disease: neurological features and diagnosis tests. Lancet 1997;350:903-907.

  35. Kurtis JD, Strobl FJ. Infectious complications of transfusion. Other transfusion-transmitted infections. In: Hillyer CD, Hillyer KL, Strobl FJ, Jefferies LC, Silberstein LE. Handbook of transfusion medicine. San Diego. CA, USA: Academic Press; 2001. p. 301-306.

  36. Brown P. Can Creutzfeld-Jakob disease be transmitted by transfusion? Curr Opin Hematol 1995;2:472-477.

  37. Turner ML, Ironside JW. New variant Creutzfeld-Jakob disease: the risk transmission by blood transfusion. Blood Rev 1998;12:255-268.

  38. 1. Menitove JE. Satandar for blood banks and transfusion services. 19th ed. Bethesda, MD, USA: 1995:51-60

  39. 2. Inaipil SV, Romero LD, Santiago SC, Ramos GA, Rangel RS, Paquini MM, Castellanos CC. Estudio comparativo de plaquetoferesis para evaluar la eficiencia en la cámara PLT-30 vs A-35 del separador celular CS 3000 plus. Memorias de la Reunión Anual de Investigación. Hospital Infantil de México Federico Gómez; 2002.

  40. 3. Calhoun L. Blood product preparation and administration. In: Petz LD, Swisher SN, Kleinman s, et al, editors. Clinical practice of transfusion medicine. 3rd ed. New York: Churchill Livingstone; 1996. p. 305-333.

  41. 4. Dzik S. Leukodepletion blood filters: filter design and mechanisms of leukocyte removal. Tranfus Med Rev 1993;7:65-77.

  42. 5. Leukocyte reduction. Association Bulletin 99-7. Bethesda, MD, USA: American Association of blod banks, 1999.

  43. 6. Buchholz DH, Aubuchon JP, Snyder EL, et al. Effects of white cell reduction on the resistance of blood components to bacterial multiplication. Transfusion 1994;34:852-857.

  44. 7. Brand A. Passenger leukocytes, cytokines and transfusion reactions. N Engl J Med 1994;331:670-671.

  45. 8. Dzik WH. Is the febrile response to transfusion due to donor or recipient cytokines ? (letter). Transfusion 1992;32:594.

  46. 9. Popovky MA, Moore SB. Diagnostic and pathogenetic consideration in transfusion 1985;25:573-577.

  47. Clay ME, Stroncek DF. Granulocyte immunology. In Anderson KC, Ness PM. editors. Scientific basis of transfusion medicine. Philadelphia, PA, USA: WB Saunders. 1994. p. 244-279.




2020     |     www.medigraphic.com